Investor Relations We are a clinical-stage biopharmaceutical company focused on metabolic and endocrine disorders. We improve compliance, absorption, and more with our proprietary drug delivery technology. Email Alerts Investors: Overview Press Releases Events and Presentations Financials & Filings Stock Information Investor FAQs Contact Us Events Presentations H.C. Wainwright 4th Annual NASH Investor Conference Monday, October 5, 2020 3:30pm EDT Listen to the Webcast